EHA26: BMS touts positive multiple myeloma data for two pipeline candidates - Clinical Trials Arena

EHA26: BMS touts positive multiple myeloma data for two pipeline candidates  Clinical Trials Arena

Edgewise data power rival to BMS and Cytokinetics toward phase 3 - Fierce Biotech

Edgewise data power rival to BMS and Cytokinetics toward phase 3  Fierce Biotech

Biopharma bites: Moderna welcomes ex-BMS, Novartis exec, plus heart benefits from COVID-19 shots ...

Biopharma bites: Moderna welcomes ex-BMS, Novartis exec, plus heart benefits from COVID-19 shots  FirstWord Pharma

Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short - BioSpace

Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short  BioSpace

Bristol Myers Squibb Announces Dividend - Yahoo Finance

Bristol Myers Squibb Announces Dividend  Yahoo Finance

Nemo project presents smart BMS for electric vehicles - electrive.com

Nemo project presents smart BMS for electric vehicles  electrive.com

New Hall of Fame class made impact at BMS - Kingsport Times News

New Hall of Fame class made impact at BMS  Kingsport Times News

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026 - Business Wire

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026  Business Wire

Robert Plenge, MD, PhD - Bristol Myers Squibb

Robert Plenge, MD, PhD  Bristol Myers Squibb

Bristol Myers Squibb Appoints GM of Saudi Arabia and Gulf Countries - Contract Pharma

Bristol Myers Squibb Appoints GM of Saudi Arabia and Gulf Countries  Contract Pharma

BMS under pressure in schizophrenia; Summit/Akeso on a winning streak - Pharma Voice

BMS under pressure in schizophrenia; Summit/Akeso on a winning streak  Pharma Voice

BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows - Fier...

BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows  Fierce Pharma

Takeda’s TYK2 inhibitor beats BMS’ Sotyktu in psoriasis showdown - Fierce Biotech

Takeda’s TYK2 inhibitor beats BMS’ Sotyktu in psoriasis showdown  Fierce Biotech

ASCO26: BMS and J&J debut shining multiple myeloma data - Clinical Trials Arena

ASCO26: BMS and J&J debut shining multiple myeloma data  Clinical Trials Arena

Survivorship Today: Cancer survivor stories - Bristol Myers Squibb

Survivorship Today: Cancer survivor stories  Bristol Myers Squibb

Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes - Yahoo ...

Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes  Yahoo Finance

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaig...

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease  Bristol Myers Squibb

ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on ...

ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice  Fierce Biotech

Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026 - Bristol ...

Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026  Bristol Myers Squibb

ASCO: In next-gen IO race, BioNTech/BMS and Pfizer are divided on overall survival approach - Fie...

ASCO: In next-gen IO race, BioNTech/BMS and Pfizer are divided on overall survival approach  Fierce Biotech

Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial - BioSpace

Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial  BioSpace

US legislation targets China pharma IP licensing following multi-billion Pfizer, BMS deals - IAM ...

US legislation targets China pharma IP licensing following multi-billion Pfizer, BMS deals  IAM Patent

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in M...

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years  Bristol Myers Squibb

The Time Back campaign honors the most precious gift oncologists provide in cancer care: time - B...

The Time Back campaign honors the most precious gift oncologists provide in cancer care: time  Bristol Myers Squibb

‘Law & Order’ star Mariska Hargitay teams up with BMS to investigate multiple myeloma research in...

‘Law & Order’ star Mariska Hargitay teams up with BMS to investigate multiple myeloma research in awareness campaign  Fierce Pharma

Advancements in psoriatic arthritis research and care - Bristol Myers Squibb

Advancements in psoriatic arthritis research and care  Bristol Myers Squibb

Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed - Fierc...

Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed  Fierce Biotech

Redefining biologics & cell therapy manufacturing at Devens - Bristol Myers Squibb

Redefining biologics & cell therapy manufacturing at Devens  Bristol Myers Squibb

BMS looks at Houston for potential $1B manufacturing plant - Fierce Pharma

BMS looks at Houston for potential $1B manufacturing plant  Fierce Pharma

Addressing disparities and innovation in multiple myeloma - Bristol Myers Squibb

Addressing disparities and innovation in multiple myeloma  Bristol Myers Squibb

ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study - Fierce Biotech

ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study  Fierce Biotech

Schneider Electric launches AI-driven continuous BMS monitoring service - Facilities Dive

Schneider Electric launches AI-driven continuous BMS monitoring service  Facilities Dive

BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfol...

BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio  Fierce Pharma

Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling - BioSpace

Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling  BioSpace

BMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific - Fierce Biotech

BMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific  Fierce Biotech

Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition - ...

Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition  Fierce Pharma

Schneider Electric Launches EcoCare for BMS to Deliver Real-Time Operational Intelligence for Mod...

Schneider Electric Launches EcoCare for BMS to Deliver Real-Time Operational Intelligence for Modern Buildings  PR Newswire

BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3 - Fierce Biotech

BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3  Fierce Biotech

ASCO26: BMS's oral CELMoD more than halves myeloma progression - FirstWord Pharma

ASCO26: BMS's oral CELMoD more than halves myeloma progression  FirstWord Pharma

BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal - BioSpace

BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal  BioSpace

BMS and Hengrui forge $15.2bn alliance for early-stage drugs - Pharmaceutical Technology

BMS and Hengrui forge $15.2bn alliance for early-stage drugs  Pharmaceutical Technology

Incredible entertainment set for the BMS Fan Zone during Food City 500 weekend - Bristol Motor Sp...

Incredible entertainment set for the BMS Fan Zone during Food City 500 weekend  Bristol Motor Speedway

Driving global heart health impact through our Corporate Giving program - Bristol Myers Squibb

Driving global heart health impact through our Corporate Giving program  Bristol Myers Squibb

BMS and Oxford BioTherapeutics join forces in TCE discovery pact - Pharmaceutical Technology

BMS and Oxford BioTherapeutics join forces in TCE discovery pact  Pharmaceutical Technology

BMS brings the buzz around late-stage readouts amid a so-so Q1 - Pharmaceutical Technology

BMS brings the buzz around late-stage readouts amid a so-so Q1  Pharmaceutical Technology

Bringing life-saving medicines to more patients: Our commitment to low- and middle-income countri...

Bringing life-saving medicines to more patients: Our commitment to low- and middle-income countries  Bristol Myers Squibb

Building a healthier future together: Strengthening cancer care across Africa through partnership...

Building a healthier future together: Strengthening cancer care across Africa through partnership  Bristol Myers Squibb

A bold blueprint for transforming lupus outcomes - Bristol Myers Squibb

A bold blueprint for transforming lupus outcomes  Bristol Myers Squibb

BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut - BioSpace

BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut  BioSpace

Bristol Myers and Evinova pen global development partnership - Fierce Biotech

Bristol Myers and Evinova pen global development partnership  Fierce Biotech

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy...

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)  Bristol Myers Squibb

BMS links up with Faro to use AI to improve clinical trial protocols - Fierce Biotech

BMS links up with Faro to use AI to improve clinical trial protocols  Fierce Biotech

BMS vs. Moderna vs. Pfizer: The RNA Platform Race - Pharmaceutical Executive

BMS vs. Moderna vs. Pfizer: The RNA Platform Race  Pharmaceutical Executive

BMS, Hengrui strike $15.2B multi-asset pact - FirstWord Pharma

BMS, Hengrui strike $15.2B multi-asset pact  FirstWord Pharma

BMS teams up with Tempus to see if AI can improve clinical success - FirstWord Pharma

BMS teams up with Tempus to see if AI can improve clinical success  FirstWord Pharma

West Side (BMS) @ Aberdeen Middle School - Results - FloWrestling

West Side (BMS) @ Aberdeen Middle School - Results  FloWrestling

Schneider Electric Launches EcoCare for BMS to Support Predictive Building Operations - ARCweb.com

Schneider Electric Launches EcoCare for BMS to Support Predictive Building Operations  ARCweb.com

Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi - Bri...

Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi  Bristol Myers Squibb

Honoring oncologists through the Time Back campaign - Bristol Myers Squibb

Honoring oncologists through the Time Back campaign  Bristol Myers Squibb

JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff - Clinical Trials Arena

JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff  Clinical Trials Arena

Johnson & Johnson sued by BMS subsidiary in UPC’s first CAR-T patent dispute - IAM Patent

Johnson & Johnson sued by BMS subsidiary in UPC’s first CAR-T patent dispute  IAM Patent

Empowering patients with clarity & confidence through UPL program - Bristol Myers Squibb

Empowering patients with clarity & confidence through UPL program  Bristol Myers Squibb

BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letter...

BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters  Fierce Pharma

OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts - Fierce Pharma

OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts  Fierce Pharma

BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace

BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments  BioSpace

Eliquis resilience drives first-quarter sales beat for BMS - FirstWord Pharma

Eliquis resilience drives first-quarter sales beat for BMS  FirstWord Pharma

BMS, J&J factor in HCP education on clot-busting mechanism before milvexian data drop - Fierce Ph...

BMS, J&J factor in HCP education on clot-busting mechanism before milvexian data drop  Fierce Pharma

BMS is latest Big Pharma firm to partner with China’s Hengrui - C&EN

BMS is latest Big Pharma firm to partner with China’s Hengrui  C&EN

Strategic pathways for broader CAR T cell therapy access - Bristol Myers Squibb

Strategic pathways for broader CAR T cell therapy access  Bristol Myers Squibb

Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target - Fierc...

Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target  Fierce Biotech

Bristol Myers Squibb ties science to soccer in World Cup campaign voiced by Ali Krieger - Fierce ...

Bristol Myers Squibb ties science to soccer in World Cup campaign voiced by Ali Krieger  Fierce Pharma

Exclusive | Bristol-Myers Squibb Brings Anthropic’s Claude to 30,000 of Its Staff - WSJ

Exclusive | Bristol-Myers Squibb Brings Anthropic’s Claude to 30,000 of Its Staff  WSJ

"Too many patients in rural America face barriers to cardiovascular care — barriers that - Bristo...

"Too many patients in rural America face barriers to cardiovascular care — barriers that  Bristol Myers Squibb

BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour - BioSpace

BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour  BioSpace

Living with idiopathic pulmonary fibrosis: Jean-Michel's journey of strength, advocacy and hope -...

Living with idiopathic pulmonary fibrosis: Jean-Michel's journey of strength, advocacy and hope  Bristol Myers Squibb

Sotyktu, take 2: BMS' first-in-class pill gains FDA nod to treat psoriatic arthritis - Fierce Pharma

Sotyktu, take 2: BMS' first-in-class pill gains FDA nod to treat psoriatic arthritis  Fierce Pharma

Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis - Fie...

Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis  Fierce Biotech

Tempus broadens collaboration with BMS for clinical trials - Clinical Trials Arena

Tempus broadens collaboration with BMS for clinical trials  Clinical Trials Arena

BMS and Hengrui Partner on 13 Oncology, Hematology, and Immunology Programs in Deal Worth Potenti...

BMS and Hengrui Partner on 13 Oncology, Hematology, and Immunology Programs in Deal Worth Potentially $15.2 Billion  BioPharm International

BMS brings 'Emily in Paris' star and cancer survivor Ashley Park aboard campaign honoring oncolog...

BMS brings 'Emily in Paris' star and cancer survivor Ashley Park aboard campaign honoring oncologists  Fierce Pharma

Nurse practitioners impact patient care and foster collaboration - Bristol Myers Squibb

Nurse practitioners impact patient care and foster collaboration  Bristol Myers Squibb

Schizophrenia Care and Evidence-Based Approaches - National Council for Mental Wellbeing

Schizophrenia Care and Evidence-Based Approaches  National Council for Mental Wellbeing

Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B - Fierce ...

Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B  Fierce Biotech

BMS says second of its two CELMoDs succeeded in Phase III myeloma study - FirstWord Pharma

BMS says second of its two CELMoDs succeeded in Phase III myeloma study  FirstWord Pharma

Cytokinetics gets jump on BMS as Myqorzo succeeds in non-obstructive HCM trial - FirstWord Pharma

Cytokinetics gets jump on BMS as Myqorzo succeeds in non-obstructive HCM trial  FirstWord Pharma

Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesi...

Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration  Pharmaceutical Executive

BMS positions Cobenfy as safer alternative ahead of pivotal Alzheimer’s psychosis readout - BioSpace

BMS positions Cobenfy as safer alternative ahead of pivotal Alzheimer’s psychosis readout  BioSpace

Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist - Yahoo Finance

Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist  Yahoo Finance

Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial - Fierce ...

Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial  Fierce Biotech

Veterans redefining manufacturing leadership in pharma - Bristol Myers Squibb

Veterans redefining manufacturing leadership in pharma  Bristol Myers Squibb

Bristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement - CHEManager

Bristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement  CHEManager

Biopharma bites: Deal details from Gilead, BMS and Garda, plus more from MacroGenics, Idorsia - F...

Biopharma bites: Deal details from Gilead, BMS and Garda, plus more from MacroGenics, Idorsia  FirstWord Pharma

FDA Action Alert: BMS, GSK, Aldeyra and More - BioSpace

FDA Action Alert: BMS, GSK, Aldeyra and More  BioSpace

BMS pens $850M solid tumor pact with T-cell engager biotech Janux - Fierce Biotech

BMS pens $850M solid tumor pact with T-cell engager biotech Janux  Fierce Biotech

BMS and Anthropic collaborate for Claude implementation - Pharmaceutical Technology

BMS and Anthropic collaborate for Claude implementation  Pharmaceutical Technology

BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration - Genetic Engineering an...

BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration  Genetic Engineering and Biotechnology News

Battle Management System: Two decades of revolutionizing the battlespace - navsea.navy.mil

Battle Management System: Two decades of revolutionizing the battlespace  navsea.navy.mil

Tom Black to Lead BMS - WRBI Radio

Tom Black to Lead BMS  WRBI Radio

Trials to Transformation: How challenges can lead to triumphs - Bristol Myers Squibb

Trials to Transformation: How challenges can lead to triumphs  Bristol Myers Squibb

BMS Names Dr. Harald Hampel SVP, Global Neuroscience Head - Contract Pharma

BMS Names Dr. Harald Hampel SVP, Global Neuroscience Head  Contract Pharma